Geron Corp (GERN)
3.93
-0.02
(-0.51%)
USD |
NASDAQ |
May 03, 16:00
3.925
0.00 (0.00%)
Pre-Market: 20:00
Geron Research and Development Expense (Annual): 125.05M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 125.05M |
| December 31, 2022 | 95.52M |
| December 31, 2021 | 85.73M |
| December 31, 2020 | 51.49M |
| December 31, 2019 | 52.07M |
| December 31, 2018 | 13.43M |
| December 31, 2017 | 11.03M |
| December 31, 2016 | 18.05M |
| December 31, 2015 | 17.83M |
| December 31, 2014 | 20.71M |
| December 31, 2013 | 23.16M |
| December 31, 2012 | 51.37M |
| December 31, 2011 | 69.32M |
| December 31, 2010 | 61.69M |
| Date | Value |
|---|---|
| December 31, 2009 | 57.62M |
| December 31, 2008 | 53.66M |
| December 31, 2007 | 54.62M |
| December 31, 2006 | 41.23M |
| December 31, 2005 | 35.08M |
| December 31, 2004 | 30.08M |
| December 31, 2003 | 25.55M |
| December 31, 2002 | 29.82M |
| December 31, 2001 | 27.93M |
| December 31, 2000 | 23.55M |
| December 31, 1999 | 20.60M |
| December 31, 1998 | 15.60M |
| December 31, 1997 | 15.10M |
| December 31, 1996 | 14.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
51.49M
Minimum
2020
125.05M
Maximum
2023
81.97M
Average
85.73M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Madrigal Pharmaceuticals Inc | 272.35M |
| SELLAS Life Sciences Group Inc | 24.01M |
| Johnson & Johnson | 15.08B |
| Pfizer Inc | 10.68B |
| Immuneering Corp | 41.62M |